Pharmaceutical

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in…

7 months ago

OKYO Pharma to Present at the Bio International Convention

LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing…

7 months ago

Artelo Biosciences Announces Reverse Stock Split

Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE)…

7 months ago

IntelGenx Announces Rebranding to Nualtis, Signaling Strategic Evolution and Renewed Vision

MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- IntelGenx, a leader in oral thin film drug delivery, today announced its official…

7 months ago

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on…

7 months ago

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE…

7 months ago

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on…

7 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on…

7 months ago

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE…

7 months ago